A multicenter study involving 32 patients with EGFR-mutant NSCLC who experienced SCLC transformation after targeted therapy revealed that the most commonly used chemotherapy regimen post-transformation was etoposide combined with platinum (n=27), with a median PFS of 3.5 months. This evidence concerns the gene EGFR and small cell lung carcinoma.